# DDI Study of Etravirine and GSK1265744

> **NCT00920296** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 12 (actual)

## Conditions studied

- Healthy Subjects
- Infection, Human Immunodeficiency Virus

## Interventions

- **DRUG:** GSK1265744

## Key facts

- **NCT ID:** NCT00920296
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2010-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00920296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00920296, "DDI Study of Etravirine and GSK1265744". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT00920296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*